This announcement is a separate document:
力生制药：天津力生制药股份有限公司拟对外转让其持有的天津田边制药有限公司24.65%股权所涉及的天津田边制药有限公司股东全部权益价值项目资产评估报告
Tianjin Lisheng Pharmaceutical: Asset evaluation report on the total equity value project of Tianjin Tanabe Pharmaceutical Co., Ltd. shareholders involved in Tianjin Lisheng Pharmaceutical Co., Ltd.'s intention to transfer 24.65% of the shares of Tianjin Tanabe Pharmaceutical Co., Ltd. held by Tianjin Lisheng Pharmaceutical Co., Ltd. to foreign countries
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.